You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameThiothixene
Accession NumberDB01623
TypeSmall Molecule
GroupsApproved
DescriptionA thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics. [PubChem]
Structure
Thumb
Synonyms
(e)-thiothixene
cis-thiothixene
Thiothixine
Tiotixene
Tiotixeno
Tiotixenum
External Identifiers
  • NSC-108165
  • P-4657 B
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Navane Cap 2mgCapsule2 mgOralErfa Canada 2012 Inc1969-12-312015-06-05Canada
Navane Cap 5mgCapsule5 mgOralErfa Canada 2012 Inc1969-12-31Not applicableCanada
Navane Capsules 10mgCapsule10 mgOralErfa Canada 2012 Inc1969-12-312015-06-05Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ThiothixeneCapsule10 mg/1OralSandoz Inc1987-06-24Not applicableUs
ThiothixeneCapsule5 mg/1OralMylan Institutional Inc.1998-03-05Not applicableUs
ThiothixeneCapsule1 mg/1OralMylan Pharmaceuticals Inc.1987-06-23Not applicableUs
ThiothixeneCapsule2 mg/1OralREMEDYREPACK INC.2011-08-172016-10-13Us
ThiothixeneCapsule1 mg/1OralSandoz Inc1987-06-24Not applicableUs
ThiothixeneCapsule2 mg/1OralREMEDYREPACK INC.2010-12-15Not applicableUs
ThiothixeneCapsule5 mg/1OralRebel Distributors Corp1987-06-24Not applicableUs
ThiothixeneCapsule10 mg/1OralMylan Institutional Inc.1998-07-24Not applicableUs
ThiothixeneCapsule2 mg/1OralMylan Pharmaceuticals Inc.1987-06-23Not applicableUs
ThiothixeneCapsule1 mg/1OralREMEDYREPACK INC.2011-10-252016-12-02Us
ThiothixeneCapsule2 mg/1OralSandoz Inc1987-06-24Not applicableUs
ThiothixeneCapsule10 mg/1OralREMEDYREPACK INC.2007-04-24Not applicableUs
ThiothixeneCapsule10 mg/1OralREMEDYREPACK INC.2011-07-192016-10-13Us
ThiothixeneCapsule10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
ThiothixeneCapsule5 mg/1OralMylan Pharmaceuticals Inc.1987-06-23Not applicableUs
ThiothixeneCapsule5 mg/1OralREMEDYREPACK INC.2011-11-142016-11-02Us
ThiothixeneCapsule5 mg/1OralSandoz Inc1987-06-24Not applicableUs
ThiothixeneCapsule5 mg/1OralREMEDYREPACK INC.2007-05-16Not applicableUs
ThiothixeneCapsule5 mg/1OralREMEDYREPACK INC.2011-07-222016-10-13Us
ThiothixeneCapsule10 mg/1OralMylan Pharmaceuticals Inc.1987-06-23Not applicableUs
ThiothixeneCapsule5 mg/1OralCarilion Materials Management1987-06-23Not applicableUs
ThiothixeneCapsule2 mg/1OralMylan Institutional Inc.1998-03-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NavanNot Available
NavaronNot Available
OrbinamonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Thiothixene hydrochloride
ThumbNot applicableDBSALT001423
Categories
UNII7318FJ13YJ
CAS number3313-26-6
WeightAverage: 443.625
Monoisotopic: 443.170118567
Chemical FormulaC23H29N3O2S2
InChI KeyGFBKORZTTCHDGY-UWVJOHFNSA-N
InChI
InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8-
IUPAC Name
(9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide
SMILES
CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
Pharmacology
IndicationFor the management of schizophrenia.
Structured Indications
PharmacodynamicsThiothixene is an antipsychotic of the thioxanthene series. Navane possesses certain chemical and pharmacological similarities to the piperazine phenothiazines and differences from the aliphatic group of phenothiazines. Although widely used in the treatment of schizophrenia for several decades, thiothixene is seldom used today in favor of atypical antipsychotics such as risperidone.
Mechanism of actionThiothixene acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(1A) dopamine receptorProteinyes
antagonist
HumanP21728 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life10-20 hours
ClearanceNot Available
ToxicitySymptoms of overdose include central nervous system depression, coma, difficulty swallowing, dizziness, drowsiness, head tilted to the side, low blood pressure, muscle twitching, rigid muscles, salivation, tremors, walking disturbances, and weakness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Thiothixene is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineThiothixene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineThiothixene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineThiothixene may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThiothixene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Thiothixene can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Thiothixene.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Thiothixene.Approved
adipiplonThe risk or severity of adverse effects can be increased when Thiothixene is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Thiothixene.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Thiothixene.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Thiothixene.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiothixene.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Amantadine.Approved
AmiodaroneThiothixene may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Thiothixene.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amperozide.Experimental
AmphetamineThiothixene may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideThiothixene may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Apomorphine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Thiothixene.Approved, Investigational
Arsenic trioxideThiothixene may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThiothixene may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Articaine.Approved
AsenapineThiothixene may increase the QTc-prolonging activities of Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Azaperone.Vet Approved
AzelastineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Azelastine.Approved
AzithromycinThiothixene may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Thiothixene is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Thiothixene.Illicit
BedaquilineThiothixene may increase the QTc-prolonging activities of Bedaquiline.Approved
BenperidolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Thiothixene.Approved
BenzphetamineThiothixene may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Thiothixene is combined with Benzyl alcohol.Approved
BortezomibThe metabolism of Thiothixene can be decreased when combined with Bortezomib.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Thiothixene.Approved, Illicit
BromocriptineThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiothixene.Approved, Investigational
BuprenorphineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiothixene.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiothixene.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Thiothixene.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiothixene.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thiothixene.Approved
CaffeineThe metabolism of Thiothixene can be decreased when combined with Caffeine.Approved
CarbamazepineThe metabolism of Thiothixene can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Thiothixene.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carisoprodol.Approved
CeritinibThiothixene may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Thiothixene.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiothixene.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Thiothixene.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Thiothixene.Approved
ChloroquineThiothixene may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorphenamine.Approved
ChlorphentermineThiothixene may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThiothixene may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Thiothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiothixene.Approved, Vet Approved
CiprofloxacinThiothixene may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideThiothixene may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThiothixene may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThiothixene may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiothixene.Approved, Illicit
ClotrimazoleThe metabolism of Thiothixene can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThiothixene may increase the QTc-prolonging activities of Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Thiothixene.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Thiothixene.Approved, Illicit
CrizotinibThiothixene may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiothixene.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Thiothixene can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiothixene.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dapoxetine.Investigational
DeferasiroxThe serum concentration of Thiothixene can be increased when it is combined with Deferasirox.Approved, Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Thiothixene is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Thiothixene.Approved
DesipramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thiothixene.Approved
DetomidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiothixene.Approved, Vet Approved
DextroamphetamineThiothixene may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Thiothixene.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Thiothixene.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Thiothixene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Thiothixene.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Thiothixene.Approved, Illicit, Vet Approved
DiethylpropionThiothixene may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thiothixene.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiothixene.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Thiothixene.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Thiothixene.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiothixene.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiothixene.Approved, Illicit
DisopyramideThiothixene may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideThiothixene may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronThiothixene may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneThiothixene may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Thiothixene is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Illicit
DronedaroneThiothixene may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Thiothixene.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Thiothixene.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thiothixene.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Thiothixene.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Thiothixene is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Thiothixene is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Thiothixene.Approved, Investigational
EliglustatThiothixene may increase the QTc-prolonging activities of Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Thiothixene.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiothixene.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thiothixene.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Thiothixene.Approved
ErythromycinThiothixene may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThiothixene may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Thiothixene.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiothixene.Approved
EthanolThiothixene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiothixene.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Thiothixene.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Thiothixene.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiothixene.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Thiothixene.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Thiothixene.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiothixene.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thiothixene.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fexofenadine.Approved
FlecainideThiothixene may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Thiothixene.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Thiothixene.Approved, Illicit
FluoxetineThiothixene may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolThiothixene may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiothixene.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Thiothixene.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Thiothixene can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Thiothixene.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiothixene.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Thiothixene is combined with gabapentin enacarbil.Approved
Gadobenic acidThiothixene may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Thiothixene.Approved, Illicit
GemifloxacinThiothixene may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Thiothixene.Approved, Illicit
GoserelinThiothixene may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThiothixene may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Thiothixene.Approved, Illicit, Withdrawn
HaloperidolThiothixene may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Thiothixene.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Thiothixene.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Thiothixene.Approved
HydrocodoneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiothixene.Approved, Illicit
Hydroxyamphetamine hydrobromideThiothixene may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
IbutilideThiothixene may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneThiothixene may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Indalpine.Investigational, Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thiothixene.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Thiothixene.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiothixene.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Thiothixene.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lamotrigine.Approved, Investigational
LenvatinibThiothixene may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideThiothixene may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Thiothixene.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Levodopa.Approved
LevofloxacinThiothixene may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Thiothixene.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Thiothixene.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiothixene.Approved
LidocaineThe metabolism of Thiothixene can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Thiothixene.Approved, Investigational
LisdexamfetamineThiothixene may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Thiothixene.Approved
LofentanilThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lofentanil.Illicit
LopinavirThiothixene may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thiothixene.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Thiothixene.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiothixene.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Thiothixene is combined with Lu AA21004.Investigational
LumefantrineThiothixene may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Thiothixene.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Melperone.Approved
MephedroneThiothixene may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineThiothixene may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Thiothixene.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiothixene.Approved, Illicit
MequitazineThiothixene may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiothixene.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Metaxalone.Approved
MethadoneThiothixene may increase the QTc-prolonging activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Thiothixene.Approved, Illicit
MethamphetamineThiothixene may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiothixene.Approved
MethotrimeprazineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Thiothixene.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiothixene.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiothixene.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Thiothixene.Approved, Investigational
MetyrosineThiothixene may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Thiothixene can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiothixene.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Thiothixene.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Thiothixene.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Investigational
MirtazapineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAThiothixene may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Thiothixene.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Thiothixene.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Thiothixene.Approved, Investigational
MoxifloxacinThiothixene may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiothixene.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Thiothixene.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Thiothixene.Approved, Withdrawn
NevirapineThe metabolism of Thiothixene can be decreased when combined with Nevirapine.Approved
NilotinibThiothixene may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Thiothixene.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Nortriptyline.Approved
OfloxacinThiothixene may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Thiothixene.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Olopatadine.Approved
OndansetronThiothixene may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Thiothixene is combined with Opium.Approved, Illicit
OrphenadrineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Thiothixene is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Thiothixene can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiothixene.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Thiothixene.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Thiothixene.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiothixene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Thiothixene.Approved, Investigational, Vet Approved
PaliperidoneThiothixene may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatThiothixene may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParaldehydeThiothixene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Thiothixene.Approved, Investigational
PazopanibThiothixene may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThiothixene may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiothixene.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiothixene.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
PerazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Perazine.Investigational
PerflutrenThiothixene may increase the QTc-prolonging activities of Perflutren.Approved
PerospironeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiothixene.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Thiothixene.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thiothixene.Approved
PhenobarbitalThe metabolism of Thiothixene can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Phenoxyethanol.Approved
PhentermineThiothixene may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Phenytoin.Approved, Vet Approved
PimozideThiothixene may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pomalidomide.Approved
PramipexoleThiothixene may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Thiothixene.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thiothixene.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Thiothixene.Approved
PrimaquineThiothixene may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Thiothixene can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThiothixene may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Thiothixene.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Thiothixene.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiothixene.Approved, Vet Approved
PromazineThiothixene may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Promethazine.Approved
PropafenoneThiothixene may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Thiothixene.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Thiothixene.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Thiothixene is combined with PSD502.Investigational
PseudoephedrineThiothixene may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Thiothixene.Approved, Illicit
QuetiapineThiothixene may increase the QTc-prolonging activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Thiothixene.Approved
QuinidineThiothixene may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThiothixene may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thiothixene.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiothixene.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiothixene.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiothixene.Approved
RifampicinThe metabolism of Thiothixene can be increased when combined with Rifampicin.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiothixene.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ritanserin.Investigational
RitobegronThiothixene may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Thiothixene.Approved
RomifidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Romifidine.Vet Approved
RopiniroleThiothixene may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiothixene.Approved
RotigotineThiothixene may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thiothixene.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Thiothixene is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Thiothixene is combined with Sage 547.Investigational
SaquinavirThiothixene may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiothixene.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Thiothixene.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Thiothixene.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Thiothixene.Approved, Vet Approved
SimeprevirThe metabolism of Thiothixene can be decreased when combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
SotalolThiothixene may increase the QTc-prolonging activities of Sotalol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiothixene.Approved, Investigational
SulfisoxazoleThiothixene may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Thiothixene.Approved, Investigational
SuvorexantThiothixene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Thiothixene.Approved
TelavancinThiothixene may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThiothixene may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiothixene.Approved
TenofovirThe metabolism of Thiothixene can be decreased when combined with Tenofovir.Approved, Investigational
TeriflunomideThe serum concentration of Thiothixene can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Thiothixene.Approved
TetracaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetrodotoxin.Investigational
ThalidomideThiothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Thiothixene can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Thiothixene.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Thiothixene.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tiapride.Investigational
TiclopidineThe metabolism of Thiothixene can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Topiramate.Approved
ToremifeneThiothixene may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiothixene.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiothixene.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Thiothixene.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Thiothixene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiothixene.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiothixene.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Thiothixene is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Thiothixene.Approved, Investigational
VandetanibThiothixene may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe serum concentration of Thiothixene can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Thiothixene.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Thiothixene.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Thiothixene.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zimelidine.Withdrawn
ZiprasidoneThiothixene may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thiothixene.Approved, Investigational
ZolpidemThiothixene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Thiothixene.Approved
ZotepineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zotepine.Approved
ZuclopenthixolThiothixene may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AF04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9969
Blood Brain Barrier+0.9437
Caco-2 permeable-0.6277
P-glycoprotein substrateSubstrate0.8707
P-glycoprotein inhibitor IInhibitor0.9247
P-glycoprotein inhibitor IIInhibitor0.9036
Renal organic cation transporterNon-inhibitor0.5373
CYP450 2C9 substrateNon-substrate0.7951
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5269
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5406
Ames testNon AMES toxic0.651
CarcinogenicityNon-carcinogens0.8173
BiodegradationNot ready biodegradable0.947
Rat acute toxicity2.7586 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5093
hERG inhibition (predictor II)Non-inhibitor0.7259
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral2 mg
CapsuleOral5 mg
CapsuleOral10 mg
CapsuleOral1 mg/1
CapsuleOral10 mg/1
CapsuleOral2 mg/1
CapsuleOral5 mg/1
Prices
Unit descriptionCostUnit
Navane 20 mg capsule3.15USD capsule
Navane 10 mg capsule1.66USD capsule
Navane 5 mg capsule1.2USD capsule
Navane 2 mg capsule0.8USD capsule
Thiothixene 10 mg capsule0.67USD capsule
Thiothixene 5 mg capsule0.47USD capsule
Thiothixene 2 mg capsule0.31USD capsule
Thiothixene 1 mg capsule0.24USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0139 mg/mLALOGPS
logP4.01ALOGPS
logP3.36ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)8.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.86 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity137.85 m3·mol-1ChemAxon
Polarizability50.35 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiopyrans
Sub Class1-benzothiopyrans
Direct ParentThioxanthenes
Alternative Parents
Substituents
  • Thioxanthene
  • Diarylthioether
  • Benzenesulfonamide
  • N-alkylpiperazine
  • N-methylpiperazine
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Shultz PJ, Sedor JR, Abboud HE: Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64. [PubMed:3039860 ]
  2. Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886 ]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  4. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263 ]
  5. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Shultz PJ, Sedor JR, Abboud HE: Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64. [PubMed:3039860 ]
  2. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438 ]
  2. Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214 ]
  2. Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920 ]
  3. Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 14:17 / Updated on August 17, 2016 12:23